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Abstract
NFkB is an inducible transcriptional factor controlled by two principal signaling cascades and plays pivotal roles in diverse
physiological processes including inflammation, apoptosis, oncogenesis, immunity, and development. Activation of NFkB
signaling was detected in skin of SHAPRIN-deficient mice and can be diminished by an NFkB inhibitor. However, in vitro
studies demonstrated that SHARPIN activates NFkB signaling by forming a linear ubiquitin chain assembly complex with
RNF31 (HOIP) and RBCK1 (HOIL1). The inconsistency between in vivo and in vitro findings about SHARPIN’s function on NFkB
activation could be partially due to SHARPIN’s potential interactions with downstream molecules of NFkB pathway. In this
study, 17 anti-flag immunoprecipitated proteins, including TRAF2, were identified by mass spectrum analysis among
Sharpin-Flag transfected mouse fibroblasts, B lymphocytes, and BALB/c LN stroma 12 cells suggesting their interaction with
SHARPIN. Interaction between SHARPIN and TRAF2 confirmed previous yeast two hybridization reports that SHARPIN was
one TRAF2’s partners. Furthermore, luciferase-based NFkB reporter assays demonstrated that SHARPIN negatively associates
with NFkB activation, which can be partly compensated by over-expression of TRAF2. These data suggested that other than
activating NFkB signaling by forming ubiquitin ligase complex with RNF31 and RBCK1, SHARPIN may also negatively
associate with NFkB activation via interactions with other NFkB members, such as TRAF2.
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Introduction
While the protein, SHAPRIN (SHANK-associated RH domain
interacting protein), has been known about for a decade, its role in
causing immune disease and inflammation is just now becoming
appreciated. SHARPIN in the inflammatory process triggers
formation of the linear ubiquitin ligase complex (LUBAC). Lack of
the Sharpin gene and therefore the protein (SHARPIN) leads to
TNF-dependent inflammation of organs, particularly the skin,
characterized as chronic proliferative dermatitis with keratinocyte
death [1–3]. Mice deficient in Sharpin develop a severe autoin-
flammatory disorder with NFkB activation, in the absence of
infectious agents, autoantibodies, or antigen-specific autoreactive
T-cells [4]. This multiorgan-involved disorder was first described
in a spontaneous, autosomal recessive mutation in mice and was
named the chronic proliferative dermatitis mutation (CPDM,
current allele symbol: Sharpin
cpdm [5–6]. Affected mice exhibit
clinical and molecular similarities to the idiopathic hypereosino-
phil syndrome in humans with clonal expansion of B1-B cells and
CD3
+CD4
2CD8
2 T cells [7]. Affected mice develop severe, scaly,
red, ulcerated skin lesions with alopecia with systemic problems
including immune system dysfunction, disorganization of second-
ary lymphoid organs, hepatosplenomegaly, infertility due to
vaginal atresia, multiorgan granulocytosis, severe granulopoiesis,
and other abnormalities [8–10]. SHARPIN is an important
protein involved with multiple molecular pathways.
The human SHARPIN protein was first identified as a novel
postsynaptic density protein and recently was shown to play a
role in carcinogenesis [11–12]. However, no specific disease has
yet been found associated with mutations or polymorphisms in
the human SHARPIN gene. Full-length SHARPIN is predicted to
be a protein of 380 amino acids with the exon 8 splice variant
encoding 305 amino acids. Protein structural analysis suggested
it had a highly conserved ubiquitin superfamily domain,
implying that it is important in protein ubiquitination [13–14].
Protein sequence BLAST revealed significant homology with E3
ubiquitin ligase at the C terminal of SHARPIN. Protein
ubiquitination and phosphorylation are two fundamental regu-
latory post-translational modifications controlling intracellular
signaling events [15–16]. Ubiquitination of proteins involves the
concerted action of the E1 ubiquitin-activated enzyme, E2
ubiquitin-conjugated enzymes, and E3 ubiquitin-protein ligases.
Furthermore, the C-terminal region of SHARPIN shares
significant amino acid sequence identity with the N-terminal
region of RanBP-type and C3HC4-type zinc finger containing 1
(RBCK1, also known as HOIP), a protein known to function as a
protein kinase C (PKC) binding protein as well as a transcrip-
tional activator [11]. SHARPIN has significant sequence
homology of its C-terminal region, enclosing a ubiquitin-like
(UBL) domain and a ubiquitin-binding NPL4 zinc-finger domain
(NZF), with the N-terminal region of RANBP (synonym:-
HOIL1L). SHARPIN was identified as a third component of
the linear ubiquitin chain assembly complex (LUBAC), recruited
to the CD40 and TNF receptor signaling complexes together
with its other constituents, RBCK1 (HOIL1) and RNF31 (HOIP)
[1–3]. Upon binding to the LUBAC subunit RNF31, SHARPIN
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21696stimulates the formation of linear ubiquitin chains in vitro and in
vivo. Coexpression of SHARPIN and RNF31 promotes linear
ubiquitination of IKBKG(synonym: NEMO) and subsequent
activation of NFkB signaling. TRAF2 is a common signal
transducer for TNFR and CD40 that mediates activation of
NFkB [17]. A yeast two-hybrid (Y2H) screen with TRAF2 (TNF
receptor-associated factor 2) as the bait (UCSD Nature Signaling
Gateway, data center, yeast two-hybrid, http://www.signaling-
gateway.org/data/Y2H/cgi-bin/y2h_int.cgi?id=53738) identified
SHARPIN (alternative symbol: protein kinase C-interacting
protein RBCC like 1 (RBCKL1)) as one of 8 preys in B cell
lines. Primary structural analysis indicates that SHARPIN may
interact with TRAF2 by protein ubiquitination as an E3 ligase.
Interleukin 1 (IL1)-mediated activation of NFkB signaling
was shown to be one of the pathways responsible for chronic
proliferative dermatitis in Sharpin
cpdm mutant mice and an
inhibitor of NFkB signaling, bortezomib, can significantly
alleviate the skin problems [7]. NFkB signaling regulates diverse
and key cellular and organismal processes including proliferation,
differentiation, cell survival, apoptosis, immunity, and inflamma-
tion [18–20]. Dysregulation of the NFkB pathway, either by
mutation or epigenetic mechanisms, is involved in many human
and animal diseases, especially ones associated with chronic
inflammation, immunodeficiency, or cancer [21]. The transcrip-
tion factor NFkB is a complex formed by homodimerization and
heterodimerization of the NFkB family members p50 (NFkB1),
p52 (NFkB2), RelA (p65), RelB, and c-Rel [22]. NFkBi su s u a l l y
located in the cytoplasm bound to inhibitor of NFkB (IKB)
proteins. However, diverse ligands, including IL1, tumor necrosis
factor-a (TNFA) or lipopolysaccharide (LPS), bind to their
receptors, and subsequently recruit cytoplasmic components
including TRAFs, such as TRAF2 and TRAF6, to form a
transmembrane complex. Ubiquitination of TRAFs will recruit
and activate the IKK kinase complex, which in turn induces
phosphorylation, ubiquitination, and subsequent degradation of
the IKBs. The free NFkB can then translocate into the nucleus to
control various transcriptional programs.
We show here that SHARPIN interacts with TRAF2, negatively
associates with NFkB activation, and this can be partially
compensated by over expression of TRAF2 in vitro.
Methods
Plasmid construct
Regions encompassing nucleotide 372 to 1538 of the full-
length Sharpin cDNA (Thermo Scientific, Pittsburgh, PA) were
PCR amplified with the forward primer 59-GCCAAGCTTC-
TATCACGGAAGCACTCTCG-39 and the reverse primer 59-
GACGAATTCCTACTTATCGTCGTCATCCTTGTAATCGGT-
GGAAGCTGCAGCAAGA-39 (nucleotides in bold indicating
the restriction sites for HindIII and EcoRI respectively). Flag
sequence, in italics, was inserted before the stop codon of the
Sharpin coding sequences. The resulted PCR product was
sequenced to confirm no introduced mutations, digested with
HindIII and EcoRI (New England Biolabs, Ipswich, MA) in a
50 ml reaction containing 1 mg of DNA incubated for 16
hours at 37 C and then subcloned into HindIII/EcoRI
–cut pcDNA
TM3.1(+) (Invitrogen, Carlsbad, CA) creating
pcDNA
TM3.1(+)/Sharpin-Flag construct. The junction sites in-
cluding 227 nucleotides of Sharpin, 24 nucleotides of Flag, and
223 nucleotides of pcDNA
TM3.1(+) were sequenced to confirm
the right orientation of the construct. The inserted fragments
included the entire coding sequence from full-length cDNAs of
Sharpin.
Protein purification, immunoprecipitation, and mass
spectrum analysis
After three passages, the MEF cultures were homogenous and
the cells were transferred into 12-well culture dishes (5610
5) and
grown in DMEM medium supplemented with 10% FBS for 24 h
until they reached confluency. The cells were then transfected with
1.6 mg of constructs described above by Lipofectamine
TM 2000
(Invitrogen, Carlsbad, CA). After 48 h, the culture medium was
replaced by DMEM containing 500 mg/mL G418 (Invitrogen) for
2 weeks in order to eliminate non-transgenic cells [23]. Once
confluent, cells were harvested to evaluate RNA expression,
protein purification, and reporter assays.
Purification of SHARPIN-FLAG fusion protein was conducted
using lysis buffer provided with the FLAGH tagged protein
immunoprecipitation kit (Sigma, St. Louis, MO). Briefly, 1610
6
cells were resuspended in 1 ml lysis buffer supplemented with
10 mL protease inhibitor cocktail (Sigma), incubated on a shaker
for 30 minutes, and centrifuged at 12,000 g for 10 minutes.
Supernatants were stored at 270 C or on ice for immediate use.
FLAG tagged SHARPIN and its binding partners were
immunoprecipitated using an ANTI-FLAG M2 affinity gel. Briefly,
40 mL of gel were placed into an empty chromatography spin
column and the resin was collected by centrifugation then washed.
The whole cell lysate was incubated with resin in the column on a
shaker at 4 C overnight. Unbound proteins were washed away and
the binding proteins were eluted in 20 uL of the sample buffer.
FLAG-BAP protein provided by the kit was used as the positive
control and MEFs transfected with the empty pcDNA
TM3.1 vector
were used as the experimental negative control. Immunoprecipi-
tated proteins were fractionated using a Criterion XT Bis-Tris gel
(Bio-Rad, Hercules, CA). The gel was stained with Coomassie
Brilliant Blue R-250 Dye (Thermo Scientific, Rockford, IL) and
bands were cut off for mass spectroscopy.
Immunoblotting
Whole cell extracts (WCE) or immunoprecipitated proteins
were fractionated using Criterion XT Bis-Tris gel and electro-
phoretically transferred onto immune-blot polyvinylidene difluor-
ide (PVDF) membranes (Bio-Rad, Hercules, CA). The blots were
then incubated for 1 h with primary antibodies (anti-FLAG
(Sigma)) at 2.5 mg/ml in blocking buffer (5% nonfat dry milk,
0.05% Tween-20 in TBS). Membranes were then incubated with
horseradish peroxidase conjugated goat anti-rabbit IgG (Thermo
Scientific) at 1:2000 in 0.05% Tween-20 in TBS for 1 h. The blots
were developed using enhanced ECL substrate detection kit
(PerkinElmer, Waltham, MA) and then exposed using LAS-1000
plus (Fujifilm AG, Dielsdorf, Switzerland). Membranes were
reprobed with anti b-Tubulin (Cell Signaling, Danvers, MA) at
1:1000 as the experiment control.
shRNA-mediated interference
Mouse embryonic fibroblasts (MEFs) (3610
5) were placed into
each well of a 12-well plate the day before viral infection. When
cells reached 50% confluency, 1.5610
6 mouse SHARPIN shRNA
lentiviral particles (Santa Cruz, Santa Cruz, CA) containing 3
target-specific constructs were used to infect cells in Fb medium
with 10 mg/ml polybrene (Santa Cruz) [24]. The culture medium
was replaced with Fb medium without polybrene 12 h postinfec-
tion. Parallel experiments were performed using cop green
fluorescence protein (GFP) lentiviral particles to monitor and
optimize transduction efficiency. Cells infected with lentiviral
particles were selected in 2 mg/mL puromycin dihydrochloride
48 h postinfection for a period of 3 days [25].
SHARPIN in NFKB Signaling
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For NFkB luciferase assays, MEFs were seeded at 70%
confluency in 6-well plates and transfected with Lipofectamine
2000 reagent according to manufacturer’s instructions (Invitro-
gen). Cells were transiently transfected with 0.25 mg/well with the
NFkB-dependent luciferase reporter plasmid 46kBL (a gift from
Dr. Bill Sugden, University of Wisconsin-Madison, WI). Empty
pcDNA
TM3.1(+) plasmid was used to balance the plasmid DNA
amount in parallel experiments. For the luciferase assay, cells were
lysed in reporter lysis buffer (Promega, Madison, WI) and activity
was measured with the luciferase assay reagent (Promega)
according to manufacturer’s instructions. Normalization for
transfection efficiency was done by co-transfecting 500 ng of a
beta-galactosidase expression plasmid (pGK-beta-gal) and mea-
suring beta-galactosidase activity. Relative luciferase activities are
expressed as fold of activation over the activity of NFkB-
dependent luciferase reporter alone and were calculated by
dividing the values of luciferase activity with the values for beta-
galactosidase activity. Three independent experiments were
performed for each group.
Quantitative PCR
Relative semi-quantitative PCR (QPCR) was performed per
QuantiTectH SYBRH Green PCR kit from Qiagen by using an
Applied Biosystems 7500 DNA sequence detection system
(PerkinElmer Corp., Santa Clara, CA). The glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) gene was used as the control for
the calculation of delta CT. Primer sequences were as follows:
Sharpin: (f) 59-CTCTTCATCGTCTGCCCATGT-39, (r) 59-
TGATCCTGAAGGGCTGCAA-39 (108 bp); Gapdh: (f) 59-CC-
TCGTCCCGTAGACAAAATG-39, (r) 59-TCTCCACTTTGC-
CACTGCAA-39 (100 bp). All reactions were performed in
triplicate. RT-PCR data were analyzed by using the 2
2(ddCT)
method as described previously [26].
Statistical Analysis
Data were analyzed by using one-way analysis of variance
(ANOVA). Differences between groups were determined with the
Dunnett’s multiple comparisons test and the data were expressed
as (mean6standard error of the mean). Significance of differences
was taken as the level of p,0.05.
Results
SHARPIN negatively relates to NFkB activation
As reported previously, the transcription of most of the
molecules in NFkB signaling is upregulated in the skin of
Sharpin
cpdm mutant mice with loss of function of SHARPIN. The
severity of the skin lesions can be reduced with bortezomib, an
NFkB inhibitor, implicating that the activation of NFkB signaling
plays a key role in the skin phenotype caused by the loss of
SHARPIN function [7]. To test whether endogenous SHARPIN
functions as an inhibitory factor of NFkB, complete defective
SHARPIN (Sharpin
cpdm mutation), SHARPIN RNA interfered with
shRNA lentivirus (Fig. 1A–1C), and over-expression of SHAR-
PIN in a Sharpin-Flag construct were used to determine the effects
of SHARPIN on NFkB activity. Flag tag was added before the stop
codon of SHARPIN to avoid affecting SHARPIN’s function
(Fig. 1F). An NFkB (p65)-dependent luciferase reporter plasmid
was transfected into MEFs already transfected with either a mouse
specific shRNA lentiviral particles or Flag tagged Sharpin
expression plasmids and Sharpin
cpdm mutant MEFs. Expression of
Sharpin mRNA was decreased by 4 fold by RNAi knockdown and
increased by 28 folds in Sharpin-Flag construct transfected cells
(Fig. 1D). As shown in Fig. 2, although no significant differences
were observed, the DNA binding and transcriptional activities of
NFkB (p65) were marginally augmented by reduction of Sharpin
expression, reinforcing the notion that Sharpin acts as a negative
regulator of the NFkB pathway. Over-expression of Sharpin
mRNA did not significantly affect the NFkB transcriptional
activity, which might be controlled by a feedback circuit.
SHARPIN regulates NFkB activation through TRAF2
involvement
To determine the direct or indirect role of SHARPIN on NFkB
activation, the Sharpin-Flag construct was transfected into MEF, B cells,
and BLS12 cells. Whole cell extracts were immunoprecipated using a
anti-FLAG affinity gel. After immunoprecipitation, anti-FLAG
antibody was used in Western blots to detect the existence and
amount of SHARPIN-FLAG fusion protein (Fig. 1E). Western blots
revealed 5 hybridized bands among which the 45 kDa band,
indicative of the SHARPIN-FLAG fusion protein, had the strongest
intensity. Immunoprecipitated proteins using the anti-FLAG affinity
gel, were separated by 2D-PAGE gel. Bands were analyzed by mass
spectroscopy. Seventeen proteins were identified from B cells, MEF,
and BLS12 cells (Table 1). Five proteins were identical in all
cells:FYN binding protein (FYB), sodium channel, voltage-gated, type
XI, alpha (SCN11A), zinc finger protein 106 (ZFP106), serine/
threonine kinase 24 (STK24), and cut-like homeobox 1 (CUX1). Four
p r o t e i n s ,T R A F 2 ,T E K T 4 ,N S D 1 ,a n dA S A P 2 ,w e r ei d e n t i f i e da s
SHARPIN partners in B cells and BLS12 cells but not in MEFs.
TRAF2 was previously shown to bind to SHARPIN in yeast-two
hybridization studies (UCSD Nature Signaling Gateway). Data
presented here confirmed this interaction between SHARPIN and
TRAF2. CCAAT/enhancer binding protein, alpha (CEBPA) and
proteasome 26S subunit, non-ATPase, 1 (PSMD1) interacted with
SHARPIN in both BLS12 and MEF cells while adenylate cyclase
activating polypeptide 1 (ADCYAP1), ring finger protein 20
(RNF20),apoptosis-inducing factor, mitochondrion-associated 1
( A I F M 1 )w e r eu n i q u ep a r t n e r si nBc e lls. Uubiquitin carboxy-terminal
hydrolase L1(UCHL1), surfeit gene 6 (SURF6), and calpain 13
(CAPN13) were identified only in BLS12 cells as SHARPIN partners.
To further clarify the synergistic or antagonistic effect, Sharpin-
Flag construct was co-transfected with or without pcDNA-Traf2/6
into wildtype or Sharpin
cpdm mutant MEFs. As shown in Fig. 3,
SHARPIN expression inhibited TRAF2-mediated NFkB activa-
tion markedly and had a weaker but no significant inhibitory effect
(about 20% inhibition) on NFkB activation by TRAF6 compared
with NFkB activation by pcDNA-Traf2/6 alone.
Discussion
It has been two decades since the spontaneous mutant, chronic
proliferative dermatitis, was reported. Although pathological
changes have been well described [8,27], this mouse model was
not brought to the forefront until the mutated gene responsible
was identified [6]. Little was known about the mutated gene,
Sharpin, in any species [10–11,28–29]. The systemic eosinophilic
phenotypes in Sharpin
cpdm mice was proposed as a potential model
for human idiopathic hypereosinophilic syndrome based on
laboratory and clinical comparisons although this has yet to be
confirmed [7]. Activation of NFkB signaling in the skin was
identified as the primary cause of the chronic proliferative
dermatitis phenotype in Sharpin
cpdm mutant mice and inhibition
of NFkB activation by bortezormib can alleviate the skin
phenotype suggesting a treatment for some forms of hypereosino-
philic syndrome in humans.
SHARPIN in NFKB Signaling
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with SHARPIN among which TRAF2 was previously identified in
yeast-two hybrid studies. Reporter assays indicated that SHAR-
PIN negatively associates with TRAF2-mediated NFkB activation.
Although no significant decrease in NFkB activity was detected
when cells were transfected with SHARPIN alone, co-transfection
of SHARPIN and TRAF2 inhibited transcription of a luciferase-
based NFkB reporter. It could be interpreted that NFkB activation
was augmented in vivo in many types of cells in the SHAPRIN-
deficient skin, although only marginal change was observed in vitro
in mouse fibroblasts alone. By contrast, Ikeda et al demonstrated
that coexpression of SHARPIN and RNF31 promoted linear
ubiquitinization of IKBKG with subsequent activation of NFkB
signaling [1]. It is possible that the activation of NFkB signaling in
the SHARPIN and RNF31 coexpression system is partially due to
RNF31 over-expression. It may potentially be interpreted as that
SHARPIN could play opposite roles for NFkB signaling at
different points in the gene network, activating NFkB signaling by
forming linear ubiquitin chain assembly complex with RNF31, or
inhibiting NFkB signaling through interaction with downstream
NFkB members such as TRAF2. Alternatively, SHARPIN may
function differently in different cell types which is supported by the
differential results obtained in these studies in vitro as well as in
preliminary studies using a Shaprin conditional null allele in vivo
(Sundberg, unpublished data).
The Shank family of proteins are known as anchoring/scaffold
proteins containing multiple protein–protein interaction sites that
include ankyrin repeats, SH3 domain, PDZ domain, long proline-
Figure 1. Sharpin expression in mouse embryonic fibroblasts. Transfection of Flag tagged Sharpin construct or shRNA lentivirus infection
were respectively applied to mouse fibroblasts. Green fluorescent protein (GFP) labeled lentivirus were used as a control to monitor the infect
efficacy. (A) Fluorescence detection of MEFs with co-transfection of both Sharpin shRNA lentivirus and GFP labeled lentivirus; (B) Differential
interference micrograph; (C) Merged image of A and B; (D) Real-time PCR quantification of Sharpin in MEFs infected by Sharpin-shRNA or transfected
by Sharpin-flag construct; (E) Anti-FLAG Western blot after anti-FLAG affinity gel immunoprecipitation of extracts from Sharpin-flag transfected MEFs.
(F) Sequence data for the Flag tagged Sharpin construct.
doi:10.1371/journal.pone.0021696.g001
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new binding partner of Shank through the ankyrin repeat domain
of Shank1 [11]. SHARPIN is relatively abundantly expressed in
multiple organs including brain, heart, and testis. It was previously
proposed that Sharpin may have an additional function(s) besides a
role as a scaffolding partner of Shank1 [11]. Using TRAF2 as bait,
SHARPIN was identified in B cells by yeast-two hybridization. In
the study reported here, mass spectrum analysis identified 17
partners of SHARPIN from 3 types of cells, including mouse B
cells, BLS12 cells, and fibroblasts. Among 5 widely expressed
proteins of interaction with SHARPIN, FYB may bind to the SH
domain of SHARPIN regulating NFkB activation by control of
IkappaB kinase alpha/beta (IKKA/B) phosphorylation and
IKKG ubiquitination [31–32]. Sharpin may play a role in
carcinogenesis through the interaction with FYB, which binds to
FYN, a newly identified oncogene [32–33]. TRAF2 interacts with
SHARPIN in B cells and BLS12 cells, supporting the previous
yeast-two hybridization report. As shown in figure 2, decreased
expression or loss of function of SHARPIN can induce increased
NFkB activity. SHARPIN had a significant negative effect on
TRAF2-mediated NFkB activation and slightly affected TRAF6-
mediated NFkB activation (Fig. 3).
Loss of Sharpin in mice results in marked epidermal hyperplasia
with marked keratinocyte apoptosis, the latter of which is regulated
through the mitochondrial pathway in a caspase-dependent
manner [34]. Three of 17 SHARPIN’s partners play important
roles on apoptosis, including AIFM1, CAPN13, and NSD1. As
AIFM1 is a key player of mitochondrial regulation of cell death,
AIFM1 may be the most likely target of SHARPIN on
keratinocyte death in Sharpin
cpdm mice [35].
In conclusion, this study has identified proteins interacting with
SHARPIN in several signaling pathways. The Sharpin gene has a
negative effect on NFkB activation, probably through protein-
protein interaction with TRAF2 and/or FYB. Whether SHAR-
PIN eventually activates or inhibits NFkB signaling depends on its
conclusive interactions at different points on NFkB pathway,
mutations in different functional domains, or cell type. SHARPIN
may also interact with AIFM1 to regulate mitochondria-mediated
apoptosis in keratinocyte. The complex molecular functions of
SHARPIN have been largely overlooked but the development and
refinement of mouse models is this to be investigated.
Figure 2. SHARPIN is negatively related to NFkB activation.
Decreased Sharpin expression by shRNA interference or Loss of function
of Sharpin
cpdm mutation resulted in NFkB activation. On the contrary,
overexpression of Sharpin by flag tagged Sharpin has inhibition effect
on NFkB activation.
doi:10.1371/journal.pone.0021696.g002
Table 1. Proteins uniquely associated with anti-FLAG affinity gel purified SHARPIN as determined by mass spectrometry analysis in
various cells.
Symbol MGI ID B cell BLS12 MEF Function
FYB 1346327 Yes Yes Yes TCR-mediated NFkB activation
SCN11A 1345149 Yes Yes Yes neurotrophin-evoked depolarization
ZFP106 1270153 Yes Yes Yes transcription regulation
STK24 2385007 Yes Yes Yes protein (MAPK1/MAPK3) phosphorylation
CUX1 88568 Yes Yes Yes cell migration and invasion
TRAF2 101835 Yes Yes No NFkB activation
TEKT4 1919090 Yes Yes No sperm motility
NSD1 1276545 Yes Yes No apoptosis
ASAP2 2685438 Yes Yes No regulation of ARF GTPase activity
CEBPA 99480 No Yes Yes arrest cell proliferation
PSMD1 1917497 No Yes Yes proteasome complex
ADCYAP1 105094 Yes No No neural stem cell proliferation, platelet activation
RNF20 1925927 Yes No No E3 ligase activity
AIFM1 1349419 Yes No No apoptosis, apoptotic mitochondrial changes
UCHL1 103149 No Yes No Regulation of synaptic structure
SURF6 98447 No Yes No DNA binding and rRNA processing
CAPN13 2685789 No Yes No apoptosis, cell division, synaptic plasticity
doi:10.1371/journal.pone.0021696.t001
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